Moderna, Inc. and Immatics N.V. announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.7 USD | +3.76% | +8.18% | +20.61% |
May. 15 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
May. 14 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
121.4 USD | -1.13% | +2.63% | 46.55B | ||
12.7 USD | +3.76% | +8.18% | 1.31B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.61% | 1.31B | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- IMTX Stock
- News Immatics N.V.
- Moderna, Inc. and Immatics N.V. Announces Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics